Top U.S. Marijuana Stocks to Watch in October 2025The U.S. cannabis industry continues to show remarkable strength as legalization momentum grows nationwide. Analysts project the market will exceed $45 billion by 2025, reflecting strong consumer demand and expanding state-level access. In addition, the cannabis sector supports over 400,000 full-time jobs and contributes billions in tax revenue each year. Recent headlines suggest the federal government may soon revisit reclassification, fueling optimism amon ...

Key Points Tilray stock rocketed on Monday on rumors the U.S. might legalize marijuana soon. In Germany, Tilray is expanding medical marijuana production. Tilray is losing a lot of money even as its other news turns good. 10 stocks we like better than Tilray Brands › Tilray Brands (NASDAQ: TLRY) stock rocketed on Monday, soaring more than 60% after President Donald Trump posted a video on his Truth Social account promoting marijuana legalization to treat ailing senior citizens -- and covering the ...

Key Points President Trump posted a pro-marijuana video on Truth Social yesterday. Curaleaf stock promptly leapt 37%. The stock's giving back some gains today, but still looks expensive. 10 stocks we like better than Curaleaf › Curaleaf Holdings (OTC: CURLF) stock, an over-the-counter traded, Stamford, Conn.-based cannabis company, tumbled 5.9% through 11:40 a.m. ET Tuesday after soaring 37% on Monday. I don't think investors need to worry too much about the retreat, however. It looks to me a lot ...

Cannabis stocks have been on an absolute tear in the past month as investors are optimistic that marijuana will soon be legalized at the federal level in the U.S. Curaleaf (CURLF) stock has surged nearly 90% year-to-date, making it the top performer among pot stocks tracked by Barchart. The rally intensified on Monday after President Trump suggested marijuana reclassification could happen within weeks and praised CBD's potential for senior healthcare. The broader market responded enthusiastically, with th ...

公司股价表现 - 股价自2021年峰值大幅下跌 过去5年1000美元投资缩水至约200美元 [2] - 同期标普500指数同等投资增值至1878美元 表现显著优于该公司股票 [2] 行业挑战 - 面临黑市和灰市持续竞争 缺乏基本金融服务 高税率阻碍潜在客户 [1] - 美国联邦层面大麻明确非法 但各州政策不一 24个州及华盛顿特区允许医疗和娱乐用途 18个州仅允许医疗用途 8个州完全禁止 [4] 财务状况 - 近期收入持续下滑 盈利能力难以实现 [6] - 成功重组3.25亿美元信贷额度 持有1.47亿美元现金及等价物 [6] 法律环境 - 联邦层面重新规划大麻合法化进程缓慢且非立法优先事项 [5] - 企业需在生存模式下运营直至联邦法律明确 [5]

公司股价表现 - 股价表现疲软 三年内1000美元投资贬值至610美元以下 [2] - 最新财报发布后出现价格飙升 [2] 公司财务状况 - 第二季度非GAAP调整后净亏损800万美元 较上年同期盈亏平衡点恶化 [3] - 季度收入保持稳定 为3.02亿美元 与前期基本持平 [3] - 现金及受限现金同比增长近13% 达到4.01亿美元 [4] - 公司保持正向现金流 [4] 公司运营动态 - 当季新增三家药房 其中佛罗里达州两家 俄亥俄州一家 [4] - 公司仍处于扩张模式 [4] 行业政策环境 - 美国缉毒局(DEA)正在推进大麻非刑事化进程 [5] - 金融服务改革法案正在联邦层面推进 [5] - 公众对修改大麻法律的支持度较高 [5] 行业投资前景 - 大麻行业整体处于困难时期 [1] - 行业最终潜力取决于美国事实上的合法化进程 [1] - 具备充足资金实力的公司更可能度过当前行业低迷期 [5]